News – Page 1145 – Endpoints News

Incyte grabs control of a cancer drug from Calithera’s pipeline for $53M up front

9 years ago

Novo Nordisk shrugs off Brexit, unveils $144M plan for a diabetes research center at Oxford

9 years ago

Biotech execs slam Trump’s travel ban, counting the high cost to a global industry

9 years ago

Regulus ordered to remain in limbo as FDA refuses to lift hold, demanding more data on lead drug

9 years ago

Novan’s shares in meltdown following "discordant" PhIII studies of a new acne drug

9 years ago

Ouch: Eli Lilly is walking away from Adocia deal and its ultra-fast insulin — for the second time

9 years ago

Highland who? Biotech gets a $200M war chest to crack the US ADHD market

9 years ago

Jounce’s Cinderella story now includes a $102M IPO chapter

9 years ago

Novartis silently yanks a troubled biosimilar application; Chinese antibody developer draws $39M round

9 years ago

M&A is off to a hot start in 2017; Too bad we can't say the same for gender parity

9 years ago

Singapore investors at Temasek grab an $800M stake in Google’s Verily

9 years ago

Venrock stocks up on $450M Fund 8 as it prepares a new string of biotech deals

9 years ago

Endo axes R&D staff in restructuring; China biotech Connect raises $20 million

9 years ago

Celgene scoops up freshman autoimmune startup Delinia in $775M buyout

9 years ago

J&J gets a $30B Actelion buyout and a new partner as Clozel’s team spins out with the pipeline

9 years ago

An early arrival among '17 biotech IPOs, AnaptysBio keeps to its range in successful $75M play

9 years ago

Investigators detail some of the hopes – and fears – behind Cellectis' off-the-shelf CAR-T

9 years ago

Zymeworks adds a new lab for fast-growing R&D work; Novartis considers a spinoff for Alcon

9 years ago

Endpoints Video spotlight: The debate over drug pricing takes center stage in 2017

9 years ago

Experts fret over a new hiring freeze at the FDA. Will the fallout be toxic to drug reviews?

9 years ago

Eisai plots new drug applications in US, Europe and China after Lenvima scores in head-to-head liver cancer study

9 years ago

Fighting a generic onslaught, Novartis adds CAR-T to its growing list of late-stage blockbusters

9 years ago

Novartis’ biotech shopping spree stays focused on the low-budget specials of the day

9 years ago

Regeneron buys its HQ site for $720M; Fast-growing Seattle Genetics plans 200 more hires this year

9 years ago

First page Previous page 1142 1143 114411451146 1147 1148 Next page Last page